Osteoclastogenesis-related antigen, a novel molecule on mouse stromal cells, regulates osteoclastogenesis

被引:2
作者
Arai, S
Amizuka, N
Azuma, Y
Takeshita, S
Kudo, A
机构
[1] Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan
[2] Teijin Ltd, Teijin Inst Biomed Res, Tokyo, Japan
[3] Niigata Univ, Sch Dent, Dept Oral Anat, Niigata, Japan
关键词
monoclonal antibody; osteoclastogenesis-related antigen; stromal cell; osteoclast differentiation; hypercalcemia;
D O I
10.1359/jbmr.2003.18.4.686
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoclastogenesis is regulated by RANKL expressed on stromal cells. In this study, we sought to isolate a new surface molecule regulating osteoclastogenesis on stromal cells by generating monoclonal antibodies. A rat was immunized with the mouse stromal cell line, TSB13,which can support osteoclastogenesis, and a monoclonal antibody, A15-1, was obtained. A15-1 bound to a surface antigen on TSB13 cells, termed osteoclastogenesis-related antigen (OCRA), and immunoprecipitation with this antibody revealed that OCRA was a 220-kDa molecule. By means of flow cytometry, the A15-1 antigen (OCRA) was found to be expressed on various mesenchymal cell lines but not on hematopoietic cell lines, and the expression level of OCRA on the TSB13 cells was slightly increased by treatment with 1alpha,25(OH)(2)D-3. When osteoclast progenitors and TSB13 cells were co-cultured in the presence of 1alpha,25(OH)(2)D-3, the addition of A15-1 inhibited osteoclast differentiation in a dose-dependent manner; however, no significant inhibition of soluble RANKL-induced osteoclastogenesis was observed, suggesting that A15-1 inhibited only stromal cell-dependent osteoclastogenesis. The same inhibitory effect of A15-1 was also observed when primary bone marrow-derived stromal cells were used. The osteoclastogenesis-promoting effects of other osteotropic factors, such as parathyroid hormone (PTH) and interleukin (IL)-1beta, were also inhibited by A15-1. Time-course analysis of osteoclast differentiation in vitro indicated that the initial 2 days of treatment with A15-1 was sufficient for inhibition, suggesting that A15-1 inhibits the early stages of osteoclast differentiation. Finally, we investigated the in vivo effects of A15-1 on PTH-induced hypercalcemia in mice. Treatment with A15-1 significantly decreased the osteoclast surface in the PTH-administered mice. Taken together, our data indicate that OCRA, a novel A15-1-detected antigen, regulates stromal cell-dependent osteoclastogenesis.
引用
收藏
页码:686 / 695
页数:10
相关论文
共 28 条
[1]   Chinese hamster ovary cells expressing α4β1 integrin stimulate osteoclast formation in vitro [J].
Akatsu, T ;
Ono, K ;
Murakami, T ;
Katayama, Y ;
Nishikawa, M ;
Wada, S ;
Yamamoto, M ;
Kugai, N ;
Matsuura, N ;
Takada, Y ;
Nagata, N .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (08) :1251-1259
[2]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[3]   EFFECTS OF INTERLEUKIN-1 ON BONE TURNOVER IN NORMAL MICE [J].
BOYCE, BF ;
AUFDEMORTE, TB ;
GARRETT, IR ;
YATES, AJP ;
MUNDY, GR .
ENDOCRINOLOGY, 1989, 125 (03) :1142-1150
[4]   DIFFERENTIAL REGULATION OF LFA-1 AND ICAM-1 ON HUMAN PRIMARY B-LYMPHOCYTES [J].
BRANDEN, H ;
LUNDGREN, E .
CELLULAR IMMUNOLOGY, 1993, 147 (01) :64-72
[5]  
DEIRDRE RC, 1994, BLOOD, V84, P739
[6]   Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis [J].
Feuerbach, D ;
Feyen, JHM .
FEBS LETTERS, 1997, 402 (01) :21-24
[7]   Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells [J].
Hofbauer, LC ;
Lacey, DL ;
Dunstan, CR ;
Spelsberg, TC ;
Riggs, BL ;
Khosla, S .
BONE, 1999, 25 (03) :255-259
[8]   Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. [J].
Horwood, NJ ;
Elliott, J ;
Martin, TJ ;
Gillespie, MT .
ENDOCRINOLOGY, 1998, 139 (11) :4743-4746
[9]   Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [J].
Hsu, HL ;
Lacey, DL ;
Dunstan, CR ;
Solovyev, I ;
Colombero, A ;
Timms, E ;
Tan, HL ;
Elliott, G ;
Kelley, MJ ;
Sarosi, I ;
Wang, L ;
Xia, XZ ;
Elliott, R ;
Chiu, L ;
Black, T ;
Scully, S ;
Capparelli, C ;
Morony, S ;
Shimamoto, G ;
Bass, MB ;
Boyle, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3540-3545
[10]   Prostaglandin E2 induces expression of receptor activator of nuclear factor-κB ligand/osteoprotegrin ligand on pre-B cells:: Implications for accelerated osteoclastogenesis in estrogen deficiency [J].
Kanematsu, M ;
Sato, T ;
Takai, H ;
Watanabe, K ;
Ikeda, K ;
Yamada, Y .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (07) :1321-1329